Latest News
ORIC Pharmaceuticals, Inc.
- Oric Pharmaceuticals moves enozertinib into Phase 3 trial: Will ORIC hold the MA-50?
- ORIC: Enozertinib showed strong systemic and CNS responses; REDWOOD-1 is planned for H1 2027
- Form 8K Oric Pharmaceuticals Inc For: 23 October By Investing.com
- Form 8K Oric Pharmaceuticals Inc For: 23 October By Investing.com
- Oric Pharmaceuticals Presents Preclinical and Translational Data to Support the Potential of Rinzimetostat to Enhance Sensitivity to Androgen Receptor Inhibition in Prostate Cancer At Esmo Congress 2026
- Oric Pharmaceuticals Reports Enozertinib Phase 1b Results, Plans Phase 3 in 2027
- ORIC Pharmaceuticals Unveils Promising Preclinical Data on Rinzi
- Oric Pharmaceuticals announces conference call and webcast review as stock rises 3.2%
- Form 144 Oric Pharmaceuticals For: 18 October By Investing.com
- Oric® Pharmaceuticals Announces Agreement With Cancer Research UK
- Oric Pharma CFO sells $181k in shares
- Form 4 Oric Pharmaceuticals Inc For: 25 September By Investing.com
Headlines from the last 30 days, linking to the original publishers. See all market news →